ClinicalTrials.gg
CompletedNCT03294083Updated Jun 18, 2026Results posted

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

A Phase 1/2 interventional study of Pexastimogene Devacirepvec (Pexa-Vec) and Cemiplimab in Renal Cell Carcinoma, sponsored by SillaJen, Inc.. Completed at 21 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by SillaJen, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 108 studies in Carcinoma, Renal Cell with a site in Korea, Republic of — 19 open to participants now, 39 under way, 13 of them phase 3. Carcinoma, Renal Cell · Korea, Republic of.

Enrollment
72nd of 93
95 · median 223
Started
2018
with 3 others
Phase 1/2
19 of 108
10 open now
Registered
57th of 108
by date

Among the 108 studies in Carcinoma, Renal Cell with a site in Korea, Republic of, this one is the 72nd largest by enrollment of the 93 interventional ones that give a count, is one of 4 that started in 2018, is one of 19 in phase 1/2, and was the 57th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

19 of the 108 studies in Carcinoma, Renal Cell with a site in Korea, Republic of are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Carcinoma, Renal Cell with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a Phase 1b/2a, open-label, multi-center, dose-escalation and safety/efficacy evaluation trial of Pexa-Vec plus Cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with Cemiplimab will be determined, followed by an expansion stage. During the expansion patients will receive Cemiplimab alone or in combination with Pexa-Vec, which will be administered either through intravenous (IV) or intratumoral (IT) injection.

Read the detailed description

For Pexa-Vec IV infusions (Part 1 / Part 2: Arm C and Arm D): Day -7, 1, 8, and 15), patients allocated to Part 1 or Part 2: Arm C or Arm D will receive an IV infusion of Pexa-Vec in approximately 250 mL buffered saline.

For Pexa-Vec IT Injections (Part 2 Arm A + Arm B), patients in Part 2, Arm A (and those in Arm B who progress on Cemiplimab monotherapy) will receive an IT injection of Pexa-Vec in a volume of buffered saline dependent on size of tumor(s).

For administration of Cemiplimab, Cemiplimab will be administered at a dose of 350 mg IV infusion over 30 minutes (±10 minutes) every 3 weeks per manufactures guidelines.

03

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • Cancer
  • Renal cell carcinoma
  • Clear cell renal cell carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed or unresectable clear cell renal cell carcinoma (ccRCC)
  • Part 2 Arm D ONLY: Patients must be to anti or anti-PD-L1 (either as monotherapy or in-combination with other approved checkpoint inhibitors or targeted therapies according to their approved label) and patients must meet all of the following criteria:

    1. Received treatment of approved anti PD-1 or anti-PD-L1 (dosed per label of the country providing the clinical site) for at least 6 weeks. History of anti-PD-L1 only is not allowed.
    2. Progressive disease after anti PD-1 or anti-PD-L1 will be defined according to v1.1. The initial evidence of progressive disease is to be confirmed by a second assessment, no less than 4 weeks from the date of the first documented progressive disease, in the absence of rapid clinical progression. (This determination is made by the Investigator; the Sponsor will collect imaging scans for retrospective analysis. Once progressive disease is confirmed, the initial date of progressive disease documentation will be considered the date of disease progression).
    3. Documented disease progression within 12 weeks of the last dose of anti PD-1 or anti-PD-L1. Patients who were re-treated or on maintenance with anti-PD-1 or anti-PD-L1 will be allowed to enter the study as long as there is documented progressive disease within 12 weeks of the last treatment date.
  • Naive to systemic therapy for RCC or have progressed after, or were intolerant of, prior systemic therapy.
  • based on RECIST v1.1 criteria. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
  • performance status of 70-100
  • Age ≥20 years old (or appropriate age of consent for the region)
  • Adequate hematological, hepatic, and renal function

Exclusion criteria

Exclusion Criteria:

  • Known significant immunodeficiency due to underlying illness (e.g., [HIV] / acquired immune deficiency syndrome [AIDS]) and/or immune-suppressive medication including high-dose
  • Part 2 only: Arm A,B,C: Prior treatment with any anti-cancer immunotherapy, including therapy with an , anti-PD-L1, or anti-PD-L2 agent (prior IL-2 or interferon allowed) . For Part 1: patients are excluded if they were intolerant to anti-PD-1 or anti-PD-L1 targeted therapies
  • Major surgery within 4 weeks of study treatment (minor surgical procedures are allowed)
  • Ongoing severe inflammatory skin condition requiring prior medical treatment
  • History of eczema requiring prior medical treatment
  • Tumor(s) invading a major vascular structure (e.g., carotid artery) or other key anatomical structure (e.g., pulmonary airway) OR viable central nervous system
  • and/or rapidly accumulating ascites, pericardial and/or pleural effusions.
  • Symptomatic cardiovascular disease, including but not limited to significant coronary artery disease (e.g., requiring angioplasty or stenting) or congestive heart failure within the preceding 12 months.
  • Asymptomatic cardiovascular disease (current or past history) unless cardiology consultation and clearance has been obtained for study participation.
  • Inability to suspend treatment with anti-hypertensive medication for 48 hours prior to and 48 hours after all Pexa-Vec treatments
  • Use of interferon/pegylated interferon (PEG-IFN) or ribavirin that cannot be discontinued within 14 days prior to any Pexa-Vec dose
  • Known active or
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Part 1, Dose escalation 3 x 10^8 pfu

    Pexa-Vec will be administered via IV infusion at a dose of 3 x 10\^8 pfu once per week for 4 treatments. Based on the occurrence of dose-limiting toxicities, patients may subsequently be enrolled to receive Pexa-Vec on the same schedule at a dose of 3 x 10\^8 pfu. Cemiplimab will be administered via IV infusion every 3 weeks.

    Biological: Pexastimogene Devacirepvec (Pexa-Vec) · Biological: Cemiplimab

  • Experimental
    Part 1, Dose escalation 1 x 10^9 pfu

    Pexa-Vec will be administered via IV infusion at a dose of 1 x 10\^9 pfu once per week for 4 treatments. Based on the occurrence of dose-limiting toxicities, patients may subsequently be enrolled to receive Pexa-Vec on the same schedule at a dose of 1 x 10\^9 pfu.

    Biological: Pexastimogene Devacirepvec (Pexa-Vec) · Biological: Cemiplimab

  • Experimental
    Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab

    Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments. Cemiplimab will be administered via IV infusion every 3 weeks. Pexastimogene Devacirepvec (Pexa-Vec): Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells Cemiplimab: Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)

    Biological: Pexastimogene Devacirepvec (Pexa-Vec) · Biological: Cemiplimab

  • Experimental
    Part 2-Arm B, Cemiplimab

    Cemiplimab will be administered via IV infusion every 3 weeks. At disease progression, Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments. Cemiplimab will continue every 3 weeks. Pexastimogene Devacirepvec (Pexa-Vec): Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells Cemiplimab: Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)

    Biological: Pexastimogene Devacirepvec (Pexa-Vec) · Biological: Cemiplimab

  • Experimental
    Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab

    Pexa-Vec will be administered via IV infusion once per week for 4 treatments. Cemiplimab will be administered via IV infusion every 3 weeks. Pexastimogene Devacirepvec (Pexa-Vec): Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells Cemiplimab: Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)

    Biological: Pexastimogene Devacirepvec (Pexa-Vec) · Biological: Cemiplimab

  • Experimental
    Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab

    Pexa-Vec will be administered via IV infusion once per week for 4 treatments. Cemiplimab will be administered via IV infusion every 3 weeks. Pexastimogene Devacirepvec (Pexa-Vec): Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells Cemiplimab: Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)

    Biological: Pexastimogene Devacirepvec (Pexa-Vec) · Biological: Cemiplimab

Interventions

  • Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells

    Also known as: JX-594

  • BiologicalCemiplimab

    Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Participants With Adverse Events From Pexa-Vec Administered by IV Infusions or IT Injections in Combination With IV Cemiplimab

    Safety will be determined by assessing the incidence, severity, and frequency of all treatment-emergent adverse events (TEAEs), Grade 3 or greater AEs, serious adverse events (SAEs), laboratory toxicity, AEs requiring discontinuation of study agent(s), and deaths. The severity of all adverse events and laboratory abnormalities is assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. Safety is monitored from the first dose throughout the treatment period (up to a maximum of 1 year) and up to 28 days after the last dose of study treatment.

    Time frame: Through study completion without survival follow-up period, an average of 1 year

  2. Overall Response Rate

    Overall response rate (ORR) is defined as the proportion of patients whose best overall responses either complete response (CR) or partial response (PR). The best overall response is the best response recorded from the randomization until disease progression. Proportions of patients with a best overall response of CR, disappearance of all target tumors; or PR, at least 30% decrease in the sum of longest diameter of target tumors will be presented by treatment arm along with exact 95% CIs. Analyses will be performed based on central assessments using RECIST v1.1.

    Time frame: Every 9 weeks until documented progression or discontinuation beyond documented progression. After 1 year, every 12 weeks from EOT visit, up to 36 months.

  3. Number of Participants With Dose Limiting Toxicities of Pexa-Vec Administered by IV Infusions in Combination With Cemiplimab (Part 1 Only)

    Dose-limiting toxicity (DLT) was assessed to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of Pexa-Vec. Patients were observed for DLTs during the IV treatment phase through Day 29. DLTs are evaluated based on the severity and frequency of adverse events and laboratory abnormalities using NCI CTCAE Version 5.0.

    Time frame: The 29-day cycle of therapy

Secondary outcomes

  1. Progression Free Survival

    Defined as the date of the first study treatment to the date of first documented radiographic tumor progression or death due to any cause, whichever occurs first (RECIST v1.1). Progression free survival will be presented descriptively using Kaplan-Meier curves. Summary statistics from the Kaplan-Meier distributions will be determined, including median PFS and 25% and 75% quartiles with corresponding 95% CIs. The proportions of patients.

    Time frame: Every 9 weeks until documented progression or discontinuation beyond documented progression. After 1 year, every 12 weeks from EOT visit, up to 36 months

  2. Disease Control Rate

    Defined as the proportion of patients whose best overall response is either complete response (CR), partial response (PR), or stable disease (SD). (RECIST v1.1)

    Time frame: Every 9 weeks until documented progression or discontinuation beyond documented progression. After 1 year, every 12 weeks from EOT visit, up to 36 months

  3. Overall Survival

    Overall survival is defined as the time from first study treatment until death from any cause. For patients not known to have died at the time of the analysis, overall survival will be censored on the date they were last known to be alive. If a patient withdraws early, overall survival will not be censored at the date of withdrawal unless this is the date they were last known to be alive. Date of death will be obtained from the death certificate (preferable) or from a written statement from the primary care or attending physician, or from death registry data. Additionally, for censored date, the latest date of (in the following order): End of Treatment visit(EOT) / Last Radiologic Timepoint(LastRTP) / End of Study(EOS) / Last Drug Date(D.LastDrug) / before cutoff date(2023-02-16) is the censored date.

    Time frame: Every 9 weeks until documented progression or discontinuation beyond documented progression. After 1 year, every 12 weeks from EOT visit, up to 36 months

07

Results

Posted Jun 18, 2026

Participant flow

Patients with histologically or cytologically confirmed metastatic or unresectable clear cell Renal Cell Carcinoma (RCC) were recruited for this study. The recruitment took place at 17 study centers across the United States, South Korea, and Australia. The first patient was enrolled on June 19, 2018, and the last patient completed the study on February 16, 2023. It was noted that there were some recruitment limitations due to intratumoral injection constraints.

Participant flow — Overall Study
MilestonePart 1 3 x 10^8 PfuPart 1 1 x 10^9 PfuPart 2-Arm A, Pexa-Vec (IT) and CemiplimabPart 2-Arm B, CemiplimabPart 2-Arm C, Pexa-Vec (IV) and CemiplimabPart 2-Arm D, Pexa-Vec (IV) and Cemiplimab
Started3315163028
Completed006586
Not completed339112222

Outcome measures

PrimaryNumber and Percentage of Participants With Adverse Events From Pexa-Vec Administered by IV Infusions or IT Injections in Combination With IV Cemiplimab

Safety will be determined by assessing the incidence, severity, and frequency of all treatment-emergent adverse events (TEAEs), Grade 3 or greater AEs, serious adverse events (SAEs), laboratory toxicity, AEs requiring discontinuation of study agent(s), and deaths. The severity of all adverse events and laboratory abnormalities is assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. Safety is monitored from the first dose throughout the treatment period (up to a maximum of 1 year) and up to 28 days after the last dose of study treatment.

Time frame:
Through study completion without survival follow-up period, an average of 1 year
Reported as:
Count of participants · Participants
Number and Percentage of Participants With Adverse Events From Pexa-Vec Administered by IV Infusions or IT Injections in Combination With IV Cemiplimab
ParticipantsPart 1 3 x 10^8 PfuPart 1 1 x 10^9 PfuPart 2-Arm A, Pexa-Vec (IT) and CemiplimabPart 2-Arm B, CemiplimabPart 2-Arm C, Pexa-Vec (IV) and CemiplimabPart 2-Arm D, Pexa-Vec (IV) and Cemiplimab
Grade 3 or greater AEs12871213
Serious adverse events21661111
AEs requiring discontinuation of study agent(s)003122
Deaths according to NCI-CTC V5000000
PrimaryOverall Response Rate

Overall response rate (ORR) is defined as the proportion of patients whose best overall responses either complete response (CR) or partial response (PR). The best overall response is the best response recorded from the randomization until disease progression. Proportions of patients with a best overall response of CR, disappearance of all target tumors; or PR, at least 30% decrease in the sum of longest diameter of target tumors will be presented by treatment arm along with exact 95% CIs. Analyses will be performed based on central assessments using RECIST v1.1.

Time frame:
Every 9 weeks until documented progression or discontinuation beyond documented progression. After 1 year, every 12 weeks from EOT visit, up to 36 months.
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsPart 1 3 x 10^8 PfuPart 1 1 x 10^9 PfuPart 2-Arm A, Pexa-Vec (IT) and CemiplimabPart 2-Arm B, CemiplimabPart 2-Arm C, Pexa-Vec (IV) and CemiplimabPart 2-Arm D, Pexa-Vec (IV) and Cemiplimab
Overall Response Rate33.3 (NA to NA)33.3 (NA to NA)13.3 (1.7 to 40.5)12.5 (1.6 to 38.3)23.3 (9.9 to 42.3)17.9 (6.06 to 36.9)
PrimaryNumber of Participants With Dose Limiting Toxicities of Pexa-Vec Administered by IV Infusions in Combination With Cemiplimab (Part 1 Only)

Dose-limiting toxicity (DLT) was assessed to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of Pexa-Vec. Patients were observed for DLTs during the IV treatment phase through Day 29. DLTs are evaluated based on the severity and frequency of adverse events and laboratory abnormalities using NCI CTCAE Version 5.0.

Time frame:
The 29-day cycle of therapy
Reported as:
Number · participants
Number of Participants With Dose Limiting Toxicities of Pexa-Vec Administered by IV Infusions in Combination With Cemiplimab (Part 1 Only)
participantsPart 1: 3 x 10^8 PfuPart 1: 1 x 10^9 Pfu
Number of Participants With Dose Limiting Toxicities of Pexa-Vec Administered by IV Infusions in Combination With Cemiplimab (Part 1 Only)00
SecondaryProgression Free Survival

Defined as the date of the first study treatment to the date of first documented radiographic tumor progression or death due to any cause, whichever occurs first (RECIST v1.1). Progression free survival will be presented descriptively using Kaplan-Meier curves. Summary statistics from the Kaplan-Meier distributions will be determined, including median PFS and 25% and 75% quartiles with corresponding 95% CIs. The proportions of patients.

Time frame:
Every 9 weeks until documented progression or discontinuation beyond documented progression. After 1 year, every 12 weeks from EOT visit, up to 36 months
Reported as:
Median · Months
Progression Free Survival
MonthsPart 1 3 x 10^8 PfuPart 1 1 x 10^9 PfuPart 2-Arm A, Pexa-Vec (IT) and CemiplimabPart 2-Arm B, CemiplimabPart 2-Arm C, Pexa-Vec (IV) and CemiplimabPart 2-Arm D, Pexa-Vec (IV) and Cemiplimab
Progression Free SurvivalNA (NA to NA)NA (NA to NA)4.27 (2.37 to NA)5.65 (2.07 to NA)4.57 (4.34 to 15.44)6.31 (3.29 to NA)
SecondaryDisease Control Rate

Defined as the proportion of patients whose best overall response is either complete response (CR), partial response (PR), or stable disease (SD). (RECIST v1.1)

Time frame:
Every 9 weeks until documented progression or discontinuation beyond documented progression. After 1 year, every 12 weeks from EOT visit, up to 36 months
Reported as:
Number · percentage of participants
Disease Control Rate
percentage of participantsPart 1 3 x 10^8 PfuPart 1 1 x 10^9 PfuPart 2-Arm A, Pexa-Vec (IT) and CemiplimabPart 2-Arm B, CemiplimabPart 2-Arm C, Pexa-Vec (IV) and CemiplimabPart 2-Arm D, Pexa-Vec (IV) and Cemiplimab
Disease Control Rate66.6 (NA to NA)33.3 (NA to NA)60.0 (32.3 to 83.7)56.3 (29.9 to 80.2)63.3 (43.9 to 80.1)67.9 (47.6 to 84.1)
SecondaryOverall Survival

Overall survival is defined as the time from first study treatment until death from any cause. For patients not known to have died at the time of the analysis, overall survival will be censored on the date they were last known to be alive. If a patient withdraws early, overall survival will not be censored at the date of withdrawal unless this is the date they were last known to be alive. Date of death will be obtained from the death certificate (preferable) or from a written statement from the primary care or attending physician, or from death registry data. Additionally, for censored date, the latest date of (in the following order): End of Treatment visit(EOT) / Last Radiologic Timepoint(LastRTP) / End of Study(EOS) / Last Drug Date(D.LastDrug) / before cutoff date(2023-02-16) is the censored date.

Time frame:
Every 9 weeks until documented progression or discontinuation beyond documented progression. After 1 year, every 12 weeks from EOT visit, up to 36 months
Reported as:
Median · month
Overall Survival
monthPart 1 3 x 10^8 PfuPart 1 1 x 10^9 PfuPart 2-Arm A, Pexa-Vec (IT) and CemiplimabPart 2-Arm B, CemiplimabPart 2-Arm C, Pexa-Vec (IV) and CemiplimabPart 2-Arm D, Pexa-Vec (IV) and Cemiplimab
Overall SurvivalNA (NA to NA)NA (NA to NA)21.98 (21.98 to NA)20.83 (19.52 to NA)25.13 (22.01 to NA)18.53 (14.75 to NA)

Adverse events

Collected over All-Cause Mortality was assessed throughstudy completion, up to 36 months; all adverse events were collected through studycompletion with survival follow-up period, an average of 1 year". Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 3 x 10^8 Pfu1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Part 1 1 x 10^9 Pfu0/3 (0%)1/3 (33.3%)3/3 (100%)
Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab3/15 (20%)6/15 (40%)15/15 (100%)
Part 2-Arm B, Cemiplimab2/16 (12.5%)6/15 (40%)15/15 (100%)
Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab5/30 (16.7%)11/30 (36.7%)30/30 (100%)
Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab5/28 (17.9%)11/28 (39.3%)28/28 (100%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventPart 1 3 x 10^8 PfuPart 1 1 x 10^9 PfuPart 2-Arm A, Pexa-Vec (IT) and CemiplimabPart 2-Arm B, CemiplimabPart 2-Arm C, Pexa-Vec (IV) and CemiplimabPart 2-Arm D, Pexa-Vec (IV) and Cemiplimab
Atrial fibrillationCardiac disorders1/30/30/150/150/300/28
SepsisInfections and infestations0/31/30/150/150/300/28
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30/30/150/150/300/28
Spinal cord compressionNervous system disorders0/30/30/152/151/300/28
HaematuriaRenal and urinary disorders0/30/31/150/150/302/28
Histiocytosis haematophagicBlood and lymphatic system disorders0/30/30/151/150/300/28
Diabetes mellitusMetabolism and nutrition disorders0/30/30/151/150/300/28
PneumoniaInfections and infestations0/30/31/150/151/301/28
Pulmonary tuberculosisInfections and infestations0/30/31/150/150/300/28
PyrexiaGeneral disorders0/30/31/150/151/301/28
Most frequent other events
Showing 10 of 57
Most frequent other events
EventPart 1 3 x 10^8 PfuPart 1 1 x 10^9 PfuPart 2-Arm A, Pexa-Vec (IT) and CemiplimabPart 2-Arm B, CemiplimabPart 2-Arm C, Pexa-Vec (IV) and CemiplimabPart 2-Arm D, Pexa-Vec (IV) and Cemiplimab
PyrexiaGeneral disorders3/33/315/159/1530/3025/28
ChillsGeneral disorders1/32/32/152/159/3010/28
Rash pustularInfections and infestations2/31/32/151/159/307/28
HypotensionVascular disorders0/32/32/151/155/309/28
Decreased appetiteMetabolism and nutrition disorders2/30/30/154/155/307/28
HyperkalaemiaMetabolism and nutrition disorders0/32/32/150/154/302/28
RashSkin and subcutaneous tissue disorders0/32/30/152/154/302/28
NauseaGastrointestinal disorders1/31/31/155/154/3010/28
FatigueGeneral disorders1/30/32/151/154/3010/28
AnaemiaBlood and lymphatic system disorders1/31/34/151/152/307/28

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part 1 : 3 x 10^8 PfuPart 1 : 1 x 10^9 PfuPart 2-Arm A, Pexa-Vec (IT) and CemiplimabPart 2-Arm B, CemiplimabPart 2-Arm C, Pexa-Vec (IV) and CemiplimabPart 2-Arm D, Pexa-Vec (IV) and CemiplimabTotal
<=18 years0000000
Between 18 and 65 years13139202066
>=65 years202710829
Age, Continuous
Age, Continuous(years)Part 1 : 3 x 10^8 PfuPart 1 : 1 x 10^9 PfuPart 2-Arm A, Pexa-Vec (IT) and CemiplimabPart 2-Arm B, CemiplimabPart 2-Arm C, Pexa-Vec (IV) and CemiplimabPart 2-Arm D, Pexa-Vec (IV) and CemiplimabTotal
Mean59.7 ± 14.4354.3 ± 7.7758.4 ± 7.8161.0 ± 10.0360.1 ± 9.6361.3 ± 6.8160.3 ± 8.53
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 : 3 x 10^8 PfuPart 1 : 1 x 10^9 PfuPart 2-Arm A, Pexa-Vec (IT) and CemiplimabPart 2-Arm B, CemiplimabPart 2-Arm C, Pexa-Vec (IV) and CemiplimabPart 2-Arm D, Pexa-Vec (IV) and CemiplimabTotal
Female11556624
Male221011242271
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1 : 3 x 10^8 PfuPart 1 : 1 x 10^9 PfuPart 2-Arm A, Pexa-Vec (IT) and CemiplimabPart 2-Arm B, CemiplimabPart 2-Arm C, Pexa-Vec (IV) and CemiplimabPart 2-Arm D, Pexa-Vec (IV) and CemiplimabTotal
American Indian or Alaska Native0000000
Asian221416251271
Native Hawaiian or Other Pacific Islander0000101
Black or African American0000000
White111041522
More than one race0000000
Unknown or Not Reported0000011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1 : 3 x 10^8 PfuPart 1 : 1 x 10^9 PfuPart 2-Arm A, Pexa-Vec (IT) and CemiplimabPart 2-Arm B, CemiplimabPart 2-Arm C, Pexa-Vec (IV) and CemiplimabPart 2-Arm D, Pexa-Vec (IV) and CemiplimabTotal
Hispanic or Latino0010067
Not Hispanic or Latino331416302288
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(Participants)Part 1 : 3 x 10^8 PfuPart 1 : 1 x 10^9 PfuPart 2-Arm A, Pexa-Vec (IT) and CemiplimabPart 2-Arm B, CemiplimabPart 2-Arm C, Pexa-Vec (IV) and CemiplimabPart 2-Arm D, Pexa-Vec (IV) and CemiplimabTotal
United States111031521
South Korea221416251271
Australia0000213
Baseline Tumor Size
Baseline Tumor Size(Centimeters (cm))Part 1 : 3 x 10^8 PfuPart 1 : 1 x 10^9 PfuPart 2-Arm A, Pexa-Vec (IT) and CemiplimabPart 2-Arm B, CemiplimabPart 2-Arm C, Pexa-Vec (IV) and CemiplimabPart 2-Arm D, Pexa-Vec (IV) and CemiplimabTotal
Mean6.175 ± 0.502013.953 ± 7.013520.030 ± 8.889917.808 ± 10.76149.642 ± 6.391311.320 ± 9.373113.03 ± 9.26
08

Study locations

21 sites
  • Site 2644 University of California, Irvine
    Irvine, California 92868, United States
  • Site 2641 University of Miami
    Miami, Florida 33136, United States
  • Site 2643 Washington University
    St Louis, Missouri 63141, United States
  • Site 2642 Billings Clinic
    Billings, Montana 59101, United States
  • Site 2646 The Ohio State University
    Columbus, Ohio 43201, United States
  • Site 2632 Flinders Medical Centre
    Bedford Park, SA5042, Australia
  • Site 2631
    Camperdown, Australia
  • Site 2612 Kyungpook National University Chilgok Hospital
    Daegu, 41404, South Korea
  • Site 2616 Chungnam National University Hospital
    Daejeon, 35015, South Korea
  • Site 2618 Chonnam National University Hwasun Hospital
    Gwangju, 58128, South Korea
  • Site 2622 Gachon University Gil Medical Center
    Incheon, South Korea
  • Site 2614 Gyeongsang National University Hospital
    Jinju, 52727, South Korea
  • Site 2613 Dong-A University Hospital
    Pusan, 49201, South Korea
  • Site 2619 Pusan National University Hospital
    Pusan, 49241, South Korea
  • Site 2617 CHA University, CHA Bundang Medical Center
    Seongnam, 35015, South Korea
  • Site 2620 Seoul National University Bundang Hospital
    Seongnam-si, 13620, South Korea
  • Site 2615 Korea University Anam Hospital
    Seoul, 02841, South Korea
  • Site 2610 Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Site 2623 Ajou University Hospital
    Suwon, 16499, South Korea
  • Site 2625 Wonju Severance Christian Hospital
    Wŏnju, 50612, South Korea
  • Site 2624 Pusan National University Yangsan Hospital
    Yangsan, 50612, South Korea
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Feb 2023, 55 months.

Results were first posted in Jun 2026, 3 years 4 months after primary completion.

Of 70 industry-sponsored phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's 55 months is below that.

Counting every sponsor, half of 111 studies reached it within 64 months; a quarter within 45 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2017
First posted
Sep 26, 2017
StartActual
Jun 19, 2018
Primary completionActual
Feb 16, 2023
CompletionActual
Feb 16, 2023
Results first posted
Jun 18, 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03294083
Lead sponsor
SillaJen, Inc.
Responsible party
Sponsor
First posted
Sep 26, 2017
Start date
Jun 19, 2018
Primary completion
Feb 16, 2023
Completion
Feb 16, 2023
Results posted
Jun 18, 2026
Last update
Jun 18, 2026

Study contacts

SillaJen Inc.
study director · SillaJen, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: JX-594 · Cemiplimab

Start the discussion